Sarepta Therapeutics, Inc. (LON:0L35)

Sarepta Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	510.6	1,103	428.43	966.78	2,116	1,503
Short-Term Investments	289.54	251.78	1,248	1,023	-	435.92
Cash & Short-Term Investments	800.14	1,355	1,676	1,989	2,116	1,939
Cash Growth	-45.21%	-19.18%	-15.74%	-5.98%	9.15%	72.36%
Accounts Receivable	600.55	636.6	430.11	256.39	171.64	135.52
Other Receivables	9.04	13.13	6.86	5.21	0.01	3.06
Receivables	609.6	649.73	436.98	261.6	171.65	138.58
Inventory	994.04	749.96	322.86	203.97	186.21	231.96
Prepaid Expenses	34.26	30.67	27.64	29.64	30.31	32.65
Other Current Assets	218.96	288.32	115.61	73.28	100.06	143.43
Total Current Assets	2,657	3,073	2,579	2,558	2,604	2,485
Property, Plant & Equipment	514.9	488.65	357.11	244.99	236.69	282.19
Long-Term Investments	41.73	136.87	6.53	31.32	34.89	38.8
Other Intangible Assets	30.52	26.89	29.62	7.58	14.24	13.63
Other Long-Term Assets	435.68	237.3	291.99	286.62	258.06	164.9
Total Assets	3,680	3,963	3,265	3,128	3,148	2,985
Accounts Payable	136.7	214.44	164.92	95.88	76.74	111.09
Accrued Expenses	205.24	241.66	197.93	335.67	206.45	147.42
Current Portion of Long-Term Debt	-	-	105.48	-	-	-
Current Portion of Leases	10.42	13.27	-	15.49	-	-
Current Income Taxes Payable	18.73	17.39	13.77	12.52	0.22	-
Current Unearned Revenue	395.43	130.26	50.42	89.24	89.24	89.24
Other Current Liabilities	153.43	114.66	121.15	70.8	80.08	68.27
Total Current Liabilities	919.95	731.68	653.66	619.6	452.73	416.03
Long-Term Debt	1,139	1,137	1,133	1,544	1,097	992.49
Long-Term Leases	214.42	192.47	140.97	57.58	41.51	80.37
Long-Term Unearned Revenue	-	325	437	485	574.24	663.49
Other Long-Term Liabilities	48.6	49.15	41.1	36.94	54.6	70.59
Total Liabilities	2,322	2,435	2,405	2,743	2,220	2,223
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	5,844	5,739	5,305	4,297	4,135	3,610
Retained Earnings	-4,462	-4,211	-4,446	-3,910	-3,207	-2,848
Comprehensive Income & Other	-0.05	-0.22	0.92	-1.66	-0.02	0
Shareholders' Equity	1,357	1,528	859.34	384.95	928.01	761.76
Total Liabilities & Equity	3,680	3,963	3,265	3,128	3,148	2,985
Total Debt	1,364	1,343	1,379	1,617	1,138	1,073
Net Cash (Debt)	-564.15	11.92	297.29	372.02	977.48	865.71
Net Cash Growth	-	-95.99%	-20.09%	-61.94%	12.91%	119.10%
Net Cash Per Share	-5.83	0.11	3.22	4.25	12.03	11.11
Filing Date Shares Outstanding	97.71	97.03	93.86	87.98	87.15	79.42
Total Common Shares Outstanding	97.71	96.9	93.73	87.95	87.13	79.37
Working Capital	1,737	2,342	1,926	1,938	2,151	2,069
Book Value Per Share	13.89	15.77	9.17	4.38	10.65	9.60
Tangible Book Value	1,327	1,501	829.72	377.37	913.77	748.13
Tangible Book Value Per Share	13.58	15.49	8.85	4.29	10.49	9.43
Land	-	10.17	10.17	5.18	5.18	5.18
Buildings	-	51.18	48.06	47.94	47.61	39.4
Machinery	-	141.98	118.63	102.31	75.04	57.76
Construction In Progress	-	165.9	91.09	23.59	25.16	71.54
Leasehold Improvements	-	155.07	99.99	97.33	103.37	55.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.